Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

988 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
GL
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
AQ
New energy for Neue Klasse: e-cars as energy storage
AQ
Knorr Bremse : Compensation report 2023
PU
Record investments weigh on BMW profit - share price weaker
DP
New Work : Fiscal Year 2023
PU
First look at Neue Klasse as SAV: The BMW Vision Neue Klasse X.
PU
Transcript : Bayerische Motoren Werke Aktiengesellschaft, 2023 Earnings Call, Mar 21, 2024
Knorr Bremse : Presentation final figures FY23
PU
Knorr Bremse : Declaration on Corporate Governance 2023
PU
Kristen Cavallo Retires from Ad Industry
GL
Kristen Cavallo Retires from Ad Industry
AQ
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
GL
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
AQ
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
BU
Transcript : Knorr-Bremse AG, Q4 2023 Earnings Call, Feb 22, 2024
Knorr-Bremse Aktiengesellschaft: Record Year for Knorr-Bremse: Revenues, Order Intake, and Order Book at Historic Highs, Turnaround Achieved, EBIT Margin Risen
EQ
Knorr-Bremse sells Kiepe Electric to Heramba
EQ
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
GL
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
AQ
Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)
EQ
DEUTZ Aktiengesellschaft entered into an agreement-in-principle to acquire lower-power-range engines business from Rolls-Royce Power Systems AG.
CI
BMW Group Technology Office USA Celebrates 25 Years in Silicon Valley with the North American Debut of the BMW Vision Neue Klasse.
AQ
Transcript : Vivoryon Therapeutics N.V., Q3 2023 Earnings Call, Dec 06, 2023
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
GL
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
AQ
Nabaltec AG expands cooperation with OTH Amberg-Weiden
EQ
GERRY WEBER International : Re­struc­tur­ing plan of GERRY WEBER In­ter­na­tion­al AG is legally valid, measures for financial re­or­gan­isa­tion will now be im­ple­men­ted promptly
PU
DD: Knorr-Bremse AG: Frank Markus Weber, buy
EQ
GERRY WEBER International AG: Restructuring plan of GERRY WEBER International AG is legally binding 
EQ
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
GL
GERRY WEBER International AG: Essen restructuring court confirms restructuring plan
EQ
Knorr Bremse : Transcription of the Q3 2023 Conference Call
PU
Knorr Bremse : Transcription of the Q3 2023 Conference Call (englisch)
PU
Knorr-Bremse Aktiengesellschaft: Knorr-Bremse Sees Higher Profit Margin and Strong Cash Flow
EQ
Knorr Bremse : Sees Higher Profit Margin and Strong Cash Flow
PU
Transcript : Knorr-Bremse AG, Q3 2023 Earnings Call, Oct 31, 2023
Expertise built into every cell: BMW Group produces battery cell samples in Parsdorf
AQ
BMW criticizes German government and EU
DP
Transcript : Oshkosh Corporation, Q3 2023 Earnings Call, Oct 26, 2023
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision
GL
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision
AQ
Transcript : Super Retail Group Limited - Shareholder/Analyst Call
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose
GL
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders
GL
Transcript : Vivoryon Therapeutics N.V. - Special Call
Carbios : Inside Information / Other news releases
PU
BMW : fills several top management positions
PU
Gerry Weber International AG: Change in the Managing Board at GERRY WEBER
EQ
No results for this search
  1. Stock Market
  2. Advanced search
  3. Frank Weber
  4. News